Form Type: 4

SEC EDGAR Link
Accession Number:0001140361-21-013551
Date:2021-04-16
Issuer: BROOKLYN IMMUNOTHERAPEUTICS, INC. (BTX)
Original Submission Date:

Reporting Person:

FEDEROFF HOWARD J.
C/O BROOKLYN IMMUNOTHERAPEUTICS, INC.
140 58TH STREET, BUILDING A, SUITE 2100 BROOKLYN, NY 11220

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
STOCK OPTION 7.94 2021-04-16 deemed execution date A 2,627,915 (a) 2031-04-15 common stock 2,627,915 $7.94 2,627,915 direct
STOCK OPTION 7.94 2021-04-16 deemed execution date A 597,253 (a) 2031-04-15 common stock 597,253 $7.94 597,253 direct
Footnotes
IDfootnote
f1 the option vests and becomes exercisable over four years, with 656,979 shares vesting on april 16, 2022, 54,748 shares vesting on the sixteenth day of each month from may 2022 through march 2025, and the remaining 54,756 shares vesting on april 16, 2025, subject to continued service through each vesting date.
f2 the option vests and becomes exercisable in full upon the occurrence of the first approval by the food and drug administration of an investigational new drug application in connection with that certain license among the issuer, factor biosciences therapeutics limited and novellus therapeutics limited, subject to continued service through such vesting date.
WhaleWisdom Logo

Elevate your investments